Koers Lonza Group AG Deutsche Boerse AG
Aandelen
LO3
CH0013841017
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
293,9 EUR | +1,48% | -.--% | -.--% |
Omzet 2024 * | 6,64 mld. 7,28 mld. 6,8 mld. | Omzet 2025 * | 7,44 mld. 8,16 mld. 7,62 mld. | Marktkapitalisatie | 36,81 mld. 40,33 mld. 37,67 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 904 mln. 991 mln. 925 mln. | Nettowinst (verlies) 2025 * | 1,11 mld. 1,22 mld. 1,14 mld. | EV/omzet 2024 * | 5,87 x |
Nettoschuld 2024 * | 2,18 mld. 2,38 mld. 2,23 mld. | Nettoschuld 2025 * | 2,47 mld. 2,71 mld. 2,53 mld. | EV/omzet 2025 * | 5,28 x |
K/w-verhouding 2024 * |
41,3
x | K/w-verhouding 2025 * |
33,1
x | Werknemers | 18.000 |
Dividendrendement 2024 * |
0,88% | Dividendrendement 2025 * |
1,01% | Vrij verhandelbaar | 95,87% |
Recentste transcriptie over Lonza Group AG
1 dag | +1,48% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25-04-17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01-12-21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16-04-14 |
Director/Board Member | 66 | 16-04-14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05-05-22 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,67% | 42,4 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,94 mld. | |
-21,66% | 18,96 mld. | |
+29,96% | 12,3 mld. | |
-1,57% | 11,95 mld. | |
+16,03% | 11,32 mld. | |
-4,80% | 11,55 mld. | |
-4,38% | 9,5 mld. |
- Beurs
- Aandelen
- Koers LONN
- Koers LO3